Table 1

Demographic and treatment parameters of GBM patient groups

VaccineChemotherapyVaccine + ChemotherapySignificance (P)
Age53.4 ± 1355.7 ± 1054.0 ± 100.88*
Karnofsky score after vaccination84 ± 1693 ± 90.12*
Male (%)5038770.14
Nonsurvivors (%)10092770.3
>2 surgeries before vaccine (%)58.361.50.43
No chemotherapy before vaccine (%)66.761.50.58
Recurrent patients (%)50 (6/12)7.7 (1/13)61.5 (8/13)0.5
No surgery after vaccine (%)58.353.81.0
Days from surgery to vaccine115 ± 14121 ± 130.94§
Mean survival (mo)17.9 ± 1.715.9 ± 2.126 ± 3.70.047§
2-yr survival [%] (fraction)8.3 (1/12)8.3 (1/12)41.7 (5/12)<0.05
3-yr survival [%] (fraction)0 (0/12)0 (0/12)18.2 (2/11)<0.01
  • * Analysis of variance.

  • Fisher’s exact test.

  • Binomial distribution, vaccine versus vaccine + chemotherapy only.

  • § Log-rank test.

  • Binomial distribution, vaccine + chemotherapy versus all other groups. Calculations of % 2- and 3-year survival excluded censored values.